Yang Guangwei, Huang Mingjun
Achillion Pharmaceuticals, New Haven, Connecticut, USA.
Curr Protoc Pharmacol. 2010 Sep;Chapter 13:Unit 13B.1. doi: 10.1002/0471141755.ph13b01s50.
Described in this unit are protocols for evaluation of new chemical entities for activity against hepatitis C virus (HCV) using HCV replicon systems. While agents designed to target NS3 protease, NS3 helicase, and NS5B RNA polymerase can be evaluated in biochemical assays, it is important to confirm their inhibitory effect on HCV RNA replication using HCV replicon systems, especially since replication involves many components besides these enzymes. Screening of compound libraries using replicon systems has led to the discovery of replication inhibitors, which act through different viral targets.
本单元介绍了使用丙型肝炎病毒（HCV）复制子系统评估新型化学实体抗HCV活性的实验方案。虽然设计用于靶向NS3蛋白酶、NS3解旋酶和NS5B RNA聚合酶的药物可以在生化分析中进行评估，但使用HCV复制子系统确认它们对HCV RNA复制的抑制作用很重要，特别是因为复制除了这些酶之外还涉及许多成分。使用复制子系统筛选化合物文库已导致发现了通过不同病毒靶点起作用的复制抑制剂。
